A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

NCT05051579 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication LY3502970 in adults who have obesity or are overweight with weight-related health issues to see how it affects their body weight compared to a placebo.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 272 people

Who can join Ages 18–75 · all sexes

Timeline Started 2021-09 · est. completion 2022-11

Where 35 sites · Canada, Hungary, Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT05051579 ↗

Description as written by the study sponsor.

The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.

Treatments tested

LY3502970 Drug

Administered orally
Placebo Drug

Administered orally

Main thing measured	Percent Change From Baseline in Body Weight in LY3502970 and Placebo
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight and Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05051579 ↗